XML 37 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
Subsequent Events
12 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
Subsequent Event Subsequent EventIn January 2022, the Company entered into an agreement with Incyte under which Incyte reserved capacity at one of the Company’s GMP manufacturing facilities where the Company will manufacture certain bulk drug substance for Incyte. This agreement is unrelated to the Incyte agreements described in Note 10, Collaboration and Other Agreements. Under the terms of the agreement, Incyte will pay the Company an upfront fee of $10.0 million.